Register now for FREE unlimited access to Reuters.com RegisterSignage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020.
REUTERS/Andrew Kelly/File PhotoSept 21 (Reuters) - The U.S. Food and Drug Administration has approved Fennec Pharmaceuticals Inc's (FENC.O) intravenous therapy to prevent chemotherapy-induced hearing loss in children, according to the health regulator's website.
Cisplatin is used in treating a range of cancers in children such as liver, bone and brain cancer, but can cause permanent hearing loss.
Register now for FREE unlimited access to Reuters.com RegisterPedmark is now the only approved therapy to prevent cisplatin-induced hearing loss in the United States, with most patients opting for either cochlear implants or hearing aids.
Register now for FREE unlimited access to Reuters.com RegisterReporting by Raghav Mahobe and Mrinalika Roy in Bengaluru; Editing by Dhanya Ann ThoppilOur Standards: The Thomson Reuters Trust Principles.